|
|
||||||||

*
Laboratoire dImmuno-Pharmacologie Moléculaire, Institut Cochin de Génétique Moléculaire, Centre National de la Recherche Scientifique, Unité Propre de Recherche 0415, Université Paris VII, Paris, France; and
Neurotech SA, Evry, France
| Abstract |
|---|
|
|
|---|
, rat brain endothelial cells responded to MHC
class II ligands, anti-MHC class II Abs, or superantigens by
expression of IL-6 transcript and IL-6 secretion. This response was not
affected by protein kinase C depletion but was mimicked by the
cAMP-elevating agent forskolin and completely blocked by H89, an
inhibitor of cAMP-dependent protein kinase (PKA). Involvement of a
cAMP/PKA signaling pathway in response to MHC class II ligands was
further demonstrated by measure of a dose-dependent increase in cAMP
level and phosphorylation of the transcription factor
cAMP response element-binding protein (CREB). Our results indicate that
MHC class II engagement in brain endothelial cells is directly coupled
to IL-6 production via a cAMP/PKA-dependent intracellular
pathway. | Introduction |
|---|
|
|
|---|
treatment (5). Induced expression of
MHC class II molecules on these cells allows them to contribute to the
recruitment and activation of cytotoxic CD4+ T
lymphocytes in the brain (6). The capacity of MHC class II molecules to transduce signals was initially suggested by studies demonstrating that anti-MHC class II mAbs can induce cellular response in human hemopoietic cells. Alternatively, TCR activation can proceed after MHC class II engagement by microbial superantigens, which bring TCR and MHC class II in close proximity by binding to amino acid residues outside of the conventional Ag-binding groove, on both Vß and MHC class II molecules (7). Indeed, binding of microbial superantigens, such as staphylococcal enterotoxins (SE)3 A, B, or E or toxic shock syndrome toxin 1 (TSST-1), to MHC class II molecules was initially demonstrated by their ability to stimulate many T cells, in both mice and humans, in the presence of MHC class II-positive cells (for review, see 7). Although binding of SE to MHC class II molecules appears to be much less restricted than to Vß, important differences in their binding affinity and specificity to various isotypes and allotypes have been reported in mice and humans (8, 9).
In response to MHC class II ligands, downstream signaling occurs through MHC class II molecules, resulting in cytokine secretion and/or gene transcription. Such events have been reported in B lymphocytes (10, 11) or in cells induced to transiently express MHC class II molecules, such as synoviocytes and keratinocytes (12, 13). The signaling pathways involved depend on cell type or activation level. Surprisingly, little is known about endothelial cell response to MHC class II engagement.
In the present study, we used the nontransformed immortalized rat brain microvessel endothelial RBE4 cells, which have been extensively characterized by us and others and maintained in culture the phenotype of the blood-brain barrier endothelium (14, 15, 16, 17, 18, 19). We report that in RBE4 cells, MHC class II engagement by mAb or microbial superantigens induces an increase in cAMP level that leads to transcriptional regulation and secretion of IL-6. This is the first demonstration that MHC class II molecules ectopically expressed on brain endothelial cells can transduce intracellular signals leading to cytokine production and suggest that their engagement with TCR directly contributes to gene regulation in endothelial cells.
| Materials and Methods |
|---|
|
|
|---|
Recombinant rat IFN-
was purchased from Life Technologies
(Eragny, France). Human IL-1ß and TNF-
and mouse IL-6 were from
Genzyme (Cambridge, MA). Escherichia coli LPS, the calcium
ionophore A23187, PMA, and forskolin were from Sigma (St. Louis, MO).
The bacterial superantigens SEA, SEB, SEE, and TSST-1 were from Toxin
Technologies (Sarasota, FL). The mAbs IgG1 anti-rat MHC class II
RT1-B (OX6) and anti-ICAM-1 1A29 were obtained from Serotec
(Wiesbaden, Germany), the polyclonal Abs directed against CREB and
Ser133-phosphorylated CREB were from
Euromedex (Souffelweyersheim, France). The highly selective
cAMP-dependent protein kinase (PKA) inhibitor H89 was purchased from
Calbiochem (San Diego, CA).
Cell culture and treatment
RBE4 cells were grown onto type I collagen-coated dishes in
-medium/Hams F-10 (1:1; Life Technologies Gibco-BRL, Eragny,
France), supplemented with 10% FBS and 1 ng/ml basic fibroblast growth
factor (Boehringer Mannheim, Mannheim, Germany), and used between the
30th and 60th passage. RBE4 cells were seeded at
104 cells/cm2 in 6-well
dishes and incubated for 3 days in a 37°C, 5%
CO2 humidified incubator, until confluent.
Cytokine or LPS treatments were performed in fresh medium for 24
h; cell supernatants were then collected and processed for IL-6
bioassay as described below. Alternatively, cells were pretreated for
48 h in presence of 100 U/ml IFN-
to induce the expression of
MHC class II molecules, before incubation in presence of OX6 Ab or
bacterial superantigens followed by IL-6 bioassay, PCR analysis, or
cAMP accumulation assay.
Flow cytometry analysis
Subconfluent RBE4 cells were incubated in the presence of
increasing concentrations of recombinant rat IFN-
, for 48 h in
fresh complete medium. Single-cell suspensions were prepared by short
trypsin-EDTA treatment. The cells were incubated in 100 µl PBS
containing 3% FBS and 0.1% sodium azide, at a final density of 2
x 105 cells/ml, in the presence or absence
(negative control) of OX6 Ab for 30 min on ice. Afterward, cells were
washed in the same buffer and resuspended in 100 µl in the presence
of FITC-labeled goat anti-mouse Igs for another 30 min on ice.
After three washes, the cells were fixed in a final volume of 500 µl
1% paraformaldehyde, and 5000 cells were analyzed on an Epics-Elite
flow cytometer (Coulter Electronics, Hialeah, FL). Fluorescence
intensity is expressed in a logarithmic scale.
IL-6 bioassay
IL-6-dependent 7TD1 cells (20) were routinely grown, in DMEM (1 g/l glucose) supplemented with 10% FBS, 2 mM glutamine, 0.1 mM hypoxanthine, 16 µM thymidine, nonessential amino acids, 2-ME, and 200 U/ml IL-6. For IL-6 bioassay, 7TD1 cells were resuspended in the same (IL-6-free) medium at 2 x 104 cells/ml, and 100 µl of this cell suspension were added to each well of a 96-well microtiter plate, together with 100 µl serial dilutions of test samples. Dilutions of IL-6 (2200 U/ml) were used as standard. Plates were incubated for 72 h in a 37°C, 5% CO2 humidified incubator. After centrifugation, the cells were washed twice with 200 µl PBS, and 60 µl of a solution containing 3.75 mM p-nitrophenyl N-acetyl-ß-D-glucosaminide from Sigma, 50 mM sodium citrate (pH 5), and 0.25% Triton X-100 were added to each well. The reaction was stopped after 68 h at 37°C by addition of 90 µl of glycine buffer (100 mM, pH 10.4). Optical densities were measured at 405 nm in a Titertek Multiskan spectrophotometer. Results were expressed in picograms IL-6/106 cells. Preliminary experiments indicated that 7TD1 proliferation was not affected by any of the bioactive agents (cytokines, LPS, A23187, MHC class II ligands) used for stimulation of RBE4 cells.
RT-PCR analysis
Cell monolayers were lysed in guanidinium isothiocyanate, and total RNA was isolated by phenol-chloroform extraction and precipitation with isopropanol as previously described (21). RNA (35 µg) was reverse transcribed using an oligo(dT) primer and Moloney murine leukemia virus reverse transcriptase, according to the manufacturers instructions (Life Technologies Gibco-BRL, Eragny, France). The cDNAs were subjected to 30 cycles of amplification (92°C, 1 min; 45°C, 1.5 min; and 72°C, 1.5 min) using 2.5 U Thermus aquaticus polymerase (Perkin-Elmer Cetus, Norwalk, CT) in 50 µl of a buffer consisting of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 100 µg/ml gelatin, 250 µM concentrations of each deoxynucleotide triphosphate, and 250 nM concentrations of each primer. For the rat IL-6 cDNA amplification, a sense primer (5'-CAAGAGACTTCCAGCCAGTTGC-3') corresponding to nucleotides 81102 and an antisense primer (5'-TTGCCGAGTAGACCTCATAGTGACC-3') corresponding to nucleotides 694670 were purchased from Clontech (Palo Alto, CA). As an internal standard of reverse transcriptase efficiency, a set of primers specific for the human G3PDH were purchased from Clontech. All pairs of primers hybridize to different exons, allowing detection of contaminating genomic DNA in the cDNA preparations.
Amplification products were electrophoresed through a 2% agarose gel and blotted onto nylon membrane. The membrane was prehybridized for 24 h at 42°C in 4x SSC, 5x Denhardts solution, 40% deionized formamide, 50 mM sodium phosphate (pH 6.8), and 100 µg/ml heat-denatured salmon sperm DNA. Hybridization was performed in the same solution in the presence of 32P-labeled murine IL-6 cDNA probe, a 1.1-kb EcoRI restriction fragment of pHP1B5, kindly provided by Dr J. Van Snick (Ludwig Institute for Cancer Research, Brussels, Belgium). Final washes were at 42°C in 1x SSC, 0.1% SDS.
cAMP accumulation assay
RBE4 cells were grown until they reached confluence in 6-well
dishes and pretreated for 48 h in the presence of 100 U/ml
IFN-
. Cells were lysed in cold ethanol for 10 min. Amounts of cAMP
were quantified with an Amersham (Les Ulis, France) cAMP ELISA
determination kit.
Immunoblot analysis
After treatment, cells (106) were washed in ice-cold PBS and then immediately lyzed in 80 µl SDS-sample buffer. Cellular extracts were then loaded on polyacrylamide gel and submitted to electrophoresis, as previously described (19). For serial incubation of membranes, bound Abs were stripped out by incubation for 10 min in 0.1 M glycine, pH 2.5, and the membranes were reprobed with different Abs as described above.
| Results |
|---|
|
|
|---|
To identify the conditions for MHC class II expression on RBE4
cell surface flow cytometry analysis was assessed with the use of OX6
mAb. As shown in Fig. 1
, RBE4 cells did
not constitutively express MHC class II molecules. During inflammatory
diseases of the CNS, IFN-
concentration largely increases until
reaching >1000 U/ml in cerebrospinal fluid (22, 23).
Therefore we determined MHC class II expression in IFN-
-treated RBE4
cells. MHC class II expression was detected on virtually all RBE4 cells
after 48 h treatment with 50 U/ml IFN-
(Fig. 1
A).
Higher concentrations of IFN-
further increased MHC class II surface
expression (Fig. 1
B).
|
On the basis of these data, RBE4 cells were pretreated for 48
h with IFN-
(100 U/ml), before incubation for 24 h in the
presence of OX6 mAb. Treatment with OX6 mAb (10 µg/ml) induced IL-6
secretion that could be detected as early as 4 h after
stimulation. The maximum level of IL-6 secretion induced by OX6 mAb
treatment for 24 h was higher than that those obtained in response
to IL-1ß, TNF-
, IFN-
, or LPS (Table I
) and was not further increased by OX6
cross-linking with a second Abs (data not shown).
|
-activated RBE4 cells at a slightly higher level
than treatment with OX6 mAb (Fig. 2
(<10 pg
IL-6/106 cells), and thus did not express MHC
class II molecules (Fig. 2
-pretreated cells were left untreated during the
24-h incubation time of the assay (Fig. 2
|
Induction of IL-6 mRNA by MHC class II ligands
To assess whether regulation of IL-6 secretion occurs at the
transcriptional level, RT-PCR analysis was performed on total RNA
samples from unstimulated, OX6- stimulated, or SEA-stimulated RBE4
cells at different time points. As shown in Fig. 3
, a cDNA fragment of the expected size
(614 bp) and hybridizing with an IL-6 specific probe was amplified as
soon as 2 h after treatment with either OX6 or SEA and was still
detected at 24 h. G3PDH amplification was used as an internal
standard. These data establish that the induction of IL-6 production by
MHC class II ligands in RBE4 cells is correlated with the elevation of
IL-6 mRNA level in RBE4 cells.
|
Previous studies addressing the molecular basis of MHC class II signaling in B cells have pointed out the role of PKC and intracellular cAMP (24, 25, 26).
In RBE4 cells, the PKC activator PMA (160 nM) appeared as a weak inducer of IL-6 secretion (data not shown). Furthermore, cell pretreatment for 16 h with 160 nM PMA, a condition known to deplete PKC in various cell type (27) including RBE4 cells (data not shown), failed to affect the capacity of OX6 mAb to induce IL-6 secretion. These observations strongly suggest that the OX6-associated signaling pathway leading to IL-6 secretion is PKC independent.
A potential role of PKA was investigated by comparing RBE4 cell
responses to MHC class II ligands and to forskolin, a direct activator
of adenylyl cyclase and PKA pathway. As shown in Fig. 4
A, forskolin induced IL-6
secretion in a dose-dependent manner. In addition, the highly selective
PKA inhibitor H89 (28) completely blocked not only the
forskolin-induced IL-6 secretion but also IL-6 secretion induced by MHC
class II ligands, OX6 or SEA (Fig. 4
B). At the
concentrations used (3060 µM), H89 did not affect the viability of
RBE4 or 7TD1 cell lines and did not induce per se any IL-6 secretion by
RBE4 cells (Fig. 4
B).
|
To further demonstrate the induction of the PKA pathway by MHC class II
ligands, cAMP level quantification was performed in RBE4 cells. OX6 as
well as SEA induced cAMP accumulation in a dose-dependent manner (Fig. 5
): cAMP level was maximum after
treatment with 10 µg/ml OX6 mAb or SEA. Interestingly, a similar
level was measured in response to 10-7 M
forskolin, all three effectors also inducing, at those concentrations,
similar levels of secreted IL-6 (Fig. 5
). No cAMP accumulation was
detected when IFN-
pretreatment was omitted or when cells were
treated with irrelevant isotype-matched Abs (not shown).
|
MHC class II stimulation induces phosphorylation of the cAMP response element-binding protein (CREB)
Because the IL-6 promoter is under the control of a cAMP response
element (29), we intended to assess the role of the
transcription factor CREB in the response to MHC class II engagement.
The ability of CREB to activate transcription in response to cAMP is
regulated by its phosphorylation at residue
Ser133 (30). Western blot analysis
of RBE4 cell extracts from untreated or OX6 (or SEA)-treated cells was
thus performed using Abs that specifically recognize the
Ser133-phosphorylated form of CREB.
CREB was found to be phosphorylated within minutes of MHC
class II stimulation by either OX6 or SEA (Fig. 6
A, upper panels).
Phosphorylation reached a maximum between 5 and 10 min
after binding and then gradually decreased over the next 20 min. The
same blot was subjected to Western blot analysis by using anti-CREB
Abs that do not discriminate between phosphorylated and
unphosphorylated forms (Fig. 6
A, lower
panels), indicating that similar CREB quantity was loaded in all
lanes. In contrast, when cells were treated with an irrelevant
isotype-matched Ab, no change in CREB phosphorylation
was observed (not shown). OX6 cross-linking did not induce
significantly stronger CREB phosphorylation than
treatment with OX6 alone (data not shown). Pretreatment of the cells
with the specific PKA inhibitor H89 prevented the
phosphorylation of CREB by MHC class II engagement, as
well as by forskolin (Fig. 6
B, upper panels),
illustrating the major role of PKA in MHC class II-induced CREB
phosphorylation. In the same conditions, increase in
cAMP level was still observed, confirming the viability of the cells
and their ability to respond normally to stimulation (not shown).
|
| Discussion |
|---|
|
|
|---|
, MHC class II ligands induce IL-6 secretion by brain
endothelial RBE4 cells. Moreover, we show that this response occurs via
a cAMP/PKA-dependent pathway and is associated with
phosphorylation of the transcription factor
CREB.
These data indicate differences between biological activity of the
various superantigens tested, which might be directly related to
variations in fine specificity of binding. Our results suggest that
cross-linking of MHC class II molecules is not required for induction
of MHC class II-coupled signaling events and that ligand binding to
only selected epitopes of MHC class II molecules can induce IL-6
secretion by brain endothelial cells. Differences in the affinity of
enterotoxins for MHC class II may also explain the higher response
observed with SEA (31). Our results indicate that MHC
class II engagement in IFN-
-pretreated rat brain microvessel
endothelial cells can also induce cytokine secretion, as previously
reported in hemopoietic cells. Together with the previous observation
of IL-6 and IL-8 production by human rheumatoid synoviocytes in
response to SEA (12), this study demonstrates that MHC
class II molecules ectopically expressed in nonhemopoietic cells can
trigger cytokine secretion.
Two distinct signaling pathways have been shown to be activated by MHC class II engagement in professional APCs: increase in cAMP accumulation together with activation of PKC in resting B cells (25) and protein tyrosine kinase activation followed by phosphoinositide hydrolysis and calcium mobilization in monocytes and in IL-4 (or CD40 ligand)-primed B cells (32, 33). Our results indicate that IL-6 secretion by RBE4 cells, induced by MHC class II ligands, is PKC independent. In addition, investigating a putative role of protein tyrosine kinases in MHC class II signaling in these cells, we failed to detect any change in the tyrosine phosphorylation pattern of cellular proteins, or in the activity of the cytosolic protein tyrosine kinases src, lyn, or fgr, at any time after MHC class II binding (data not shown). In contrast, we show here that forskolin, a cAMP-elevating agent, can induce IL-6 production in RBE4 cells. Moreover, our observation that the highly selective PKA inhibitor H89 completely abrogates the SEA- or OX6-induced IL-6 secretion strongly suggests that activation of PKA is necessary to the induction of IL-6 production by MHC class II ligands. In agreement with this observation, we show that MHC class II engagement by OX-6 or SEA induces an increase in intracellular cAMP level. Taken together, these results demonstrate that cAMP/PKA signaling in RBE4 cells is the major pathway involved in MHC class II-induced IL-6 secretion.
IL-6 expression is regulated via various signal transduction pathways
because of the presence of several cis-regulatory elements
in the IL-6 gene promoter (34), including a cAMP response
element, which is bound by the transcription factor CREB. Multiple
pathways have recently been shown to be able to regulate CREB
phosphorylation and activity, including cAMP/PKA,
calcium signaling, MAP kinases, Erk, and p38 (35, 36, 37). In
the present study, specific inhibitors of pathways other than cAMP/PKA
did not affect MHC class II-induced CREB
phosphorylation. No activation of Erk in response to
MHC class II ligands was detected in RBE4 cells (not shown). Moreover,
CREB phosphorylation induced by MHC class II engagement
was abolished by inhibition of PKA, strongly suggesting that PKA was
entirely responsible for CREB phosphorylation. Once it
is phosphorylated, CREB can contribute directly to the
transcription of late response gene. In addition, CREB plays a key role
in the activation of immediate early genes, such as c-fos,
and may therefore be indirectly responsible for IL-6 transcription
(38). In addition to CREB, transcription factors
such as AP-1, NF-IL-6, and NF-
B may also transmit cAMP-mediated
signals to the transcriptional machinery (37, 39, 40, 41).
Thus, cAMP accumulation observed after MHC class II engagement could
activate IL-6 transcription via multiple transcription factors.
To our knowledge, these results indicate, for the first time, that MHC
class II molecules can induce intracellular signal transduction in
endothelial cells and trigger transcriptional regulation of IL-6
secretion, whereas other inflammatory cytokines such as IL-1ß and
TNF-
were not induced (data not shown). Moreover, they suggest that
brain endothelium could release IL-6 in response to MHC class II
engagement during lymphocyte adhesion and thus may participate to the
enhanced IL-6 production observed in various inflammatory diseases of
the CNS (42, 43). IL-6 expression in the brain plays an
important role in the global regulation of neurons, astrocytes, and
microglia (44, 45). Moreover, inflammatory cytokines like
IL-6 affect brain endothelium permeability to macromolecules in vitro
(46), and extensive breakdown of the blood-brain barrier
was observed in transgenic mice expressing IL-6 in astrocytes
(47). Using human brain endothelial cells in culture,
Persidsky et al. (48) recently pointed out the role of
these inflammatory cytokines in activation of cerebral endothelium and
opening of intercellular junctions, leading to enhanced migration of
HIV-infected monocytes. Induction of IL-6 secretion by brain
endothelial cells in response to MHC class II engagement with T
lymphocytes may thus participate to the local opening of the
blood-brain barrier and enhancement lymphocyte infiltration during
experimental allergic encephalomyelitis or other inflammatory diseases
of the CNS (49).
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. S. Etienne, Laboratoire dImmuno-Pharmacologie Moléculaire, Centre National de la Recherche Scientifique, Unité Propre de Recherche 0415, Institut Cochin de Génétique Moléculaire, 22 rue Méchain, 75014 Paris, France. E-mail: ![]()
3 Abbreviations used in this paper: SE, staphylococcal enterotoxin; CREB, cAMP-response-element binding protein; PKA, cAMP-dependent kinase; PKC, protein kinase C; TSST-1, toxic shock syndrome toxin 1. ![]()
Received for publication February 8, 1999.
| References |
|---|
|
|
|---|
-induced class II MHC expression on bovine brain capillary endothelial cells. J. Immunol. 147:2525.
-treated endothelial cells and fibroblasts: differential ability to function as antigen presenting cells despite comparable Ia expression. J. Immunol. 135:3750.[Abstract]
-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J. Cell. Physiol. 159:101.[Medline]
in the central nervous system during viral meningitis and encephalitis. J. Exp. Med. 168:449.
. J. Neuroimmunol. 40:211.[Medline]
and interleukin-6 on fluid phase permeability and ammonia diffusion in CNS-derived endothelial cells. J. Invest. Med. 1996:474.
This article has been cited by other articles:
![]() |
N J Abbott, L L. Mendonca, and D E. Dolman The blood-brain barrier in systemic lupus erythematosus Lupus, December 1, 2003; 12(12): 908 - 915. [Abstract] [PDF] |
||||
![]() |
H.-C. Cheng, H.-M. Shih, and Y. Chern Essential Role of cAMP-response Element-binding Protein Activation by A2A Adenosine Receptors in Rescuing the Nerve Growth Factor-induced Neurite Outgrowth Impaired by Blockage of the MAPK Cascade J. Biol. Chem., September 6, 2002; 277(37): 33930 - 33942. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. van Buul, C. Voermans, V. van den Berg, E. C. Anthony, F. P. J. Mul, S. van Wetering, C. E. van der Schoot, and P. L. Hordijk Migration of Human Hematopoietic Progenitor Cells Across Bone Marrow Endothelium Is Regulated by Vascular Endothelial Cadherin J. Immunol., January 15, 2002; 168(2): 588 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Ammit, R. K. Hoffman, Y. Amrani, A. L. Lazaar, D. W. P. Hay, T. J. Torphy, R. B. Penn, and R. A. Panettieri Jr. Tumor Necrosis Factor-alpha -Induced Secretion of RANTES and Interleukin-6 from Human Airway Smooth-Muscle Cells . Modulation by Cyclic Adenosine Monophosphate Am. J. Respir. Cell Mol. Biol., December 1, 2000; 23(6): 794 - 802. [Abstract] [Full Text] |
||||
![]() |
S. Etienne-Manneville, J.-B. Manneville, P. Adamson, B. Wilbourn, J. Greenwood, and P.-O. Couraud ICAM-1-Coupled Cytoskeletal Rearrangements and Transendothelial Lymphocyte Migration Involve Intracellular Calcium Signaling in Brain Endothelial Cell Lines J. Immunol., September 15, 2000; 165(6): 3375 - 3383. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |